BMEA

Company Overview — What Does Biomea Fusion, Inc. Do?

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California. Biomea Fusion, Inc. (BMEA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Thomas Butler and employs approximately 50 people. With a market capitalization of $108M, BMEA is one of the notable companies in the Healthcare sector.

Biomea Fusion, Inc. (BMEA) Stock Rating — Reduce (April 2026)

As of April 2026, Biomea Fusion, Inc. receives a Reduce rating with a composite score of 22.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BMEA ranks #3,260 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Biomea Fusion, Inc. ranks #493 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BMEA Stock Price and 52-Week Range

Biomea Fusion, Inc. (BMEA) currently trades at $1.82. The stock lost $0.03 (1.6%) in the most recent trading session. The 52-week high for BMEA is $3.08, which means the stock is currently trading -40.9% from its annual peak. The 52-week low is $0.87, putting the stock 108.7% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.

Is BMEA Overvalued or Undervalued? — Valuation Analysis

Biomea Fusion, Inc. (BMEA) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.65x, versus the sector average of 2.75x. The price-to-sales ratio is 25.51x, compared to 1.66x for the average Healthcare stock.

At current multiples, Biomea Fusion, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Biomea Fusion, Inc. Profitability — ROE, Margins, and Quality Score

Biomea Fusion, Inc. (BMEA) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -335.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -169.4% versus the sector average of -33.1%.

The operating margin is -3681.7% (sector: -66.1%). Net profit margin stands at -3581.7%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BMEA Debt, Balance Sheet, and Financial Health

Biomea Fusion, Inc. has a debt-to-equity ratio of 98.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 5.23x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $47M.

BMEA has a beta of 1.45, meaning it is more volatile than the broader market — a $10,000 investment in BMEA would be expected to move 44.9% more than the S&P 500 on any given day. The stability factor score for Biomea Fusion, Inc. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Biomea Fusion, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Biomea Fusion, Inc. reported revenue of $5M and earnings per share (EPS) of $-1.18. Net income for the quarter was $-99M. Operating income came in at $-106M.

In FY 2025, Biomea Fusion, Inc. reported revenue of $2M and earnings per share (EPS) of $-1.18. Net income for the quarter was $-62M. Operating income came in at $-84M.

In Q3 2025, Biomea Fusion, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.27. Net income for the quarter was $-16M. Operating income came in at $-21M.

In Q2 2025, Biomea Fusion, Inc. reported revenue of $536,000 and earnings per share (EPS) of $-0.51. Net income for the quarter was $-21M. Operating income came in at $-21M.

Over the past 8 quarters, Biomea Fusion, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $5M. Investors analyzing BMEA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BMEA Dividend Yield and Income Analysis

Biomea Fusion, Inc. (BMEA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BMEA Momentum and Technical Analysis Profile

Biomea Fusion, Inc. (BMEA) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

BMEA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Biomea Fusion, Inc. (BMEA) ranks #493 out of 838 stocks based on the Blank Capital composite score. This places BMEA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BMEA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BMEA vs S&P 500 (SPY) comparison to assess how Biomea Fusion, Inc. stacks up against the broader market across all factor dimensions.

BMEA Next Earnings Date

No upcoming earnings date has been announced for Biomea Fusion, Inc. (BMEA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BMEA? — Investment Thesis Summary

The quantitative profile for Biomea Fusion, Inc. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, Biomea Fusion, Inc. (BMEA) earns a Reduce rating with a composite score of 22.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BMEA stock.

Related Resources for BMEA Investors

Explore more research and tools: BMEA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BMEA head-to-head with peers: BMEA vs AZN, BMEA vs SLGL, BMEA vs VMD.